Oncogenic MYD88 mutation drives Toll pathway to lymphoma

Immunology and Cell Biology

Volumn 89, Issue 6, 2011, Pages 659-660

  Jeelall, Yogesh S ^a   Horikawa, Keisuke ^a  

^a Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; JANUS KINASE; MYELOID DIFFERENTIATION FACTOR 88; STAT3 PROTEIN; TOLL LIKE RECEPTOR;

ACTIVATED B CELL LYMPHOMA; AMINO ACID SUBSTITUTION; B CELL LYMPHOMA; CANCER GROWTH; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; NONHUMAN; NOTE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 80051676164     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.31     Document Type: Note

References (19)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373.
2. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsusui H, Sakagami M et al. Targeted disruption of the Myd88 gene results in loss of IL-1 and IL-18 mediated function. Immunity 1998; 9: 143.
3. Von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku C-L et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321: 691.
4. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115.
5. Staudt LM. Oncogenic activation of NF-kB. Cold Spring Harb Perspect Biol 2010; 2: a000109.
6. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417.
7. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861.
8. Ngo VN, Davis ER, Lamy L, Yu X, Zhao H, Lenz G et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106.
9. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676.
10. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romes-ser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88.
11. Compagno M, Lim WK, Grunn A, Nandula SV, Brah-machary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma. Nature 2009; 459: 717.
12. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al. Frequent inactivation of A20 in B-cell lympho-mas. Nature 2009; 459: 712.
13. Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q et al. BLIMP1 is a tumour suppressor gene frequently disrupted in Activated B cell-like diffuse large B cell lymphoma. Cancer cell 2010; 18: 568.
14. Calado DC, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C et al. Constitutive canonical NFkB activation cooperates with disruption of BLIMP1 in the pathogen-esis of Activated B cell-like diffuse large cell lym-phoma. Cancer cell 2010; 18: 580.
15. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kB pathways in subtypes of diffuse large B-cell lym-phoma. Blood 2009; 111: 3701.
16. Ding BB, Yu JJ, Yu RY-L, Mendez LM, Shaknovich R, Zhang Y et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515.
17. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterhwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312: 1669.
18. Burnet FM. Autoimmunity and Autoimmune Disease. Medical and Technical Publishing Co Ltd: Lancaster, UK, 1972.
19. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007; 130: 25.